Cargando…

Antiangiogenic activity of aplidine, a new agent of marine origin

The antineoplastic compound aplidine, a new marine-derived depsipeptide, has shown preclinical activity in vitro on haematological and solid tumour cell lines. It is currently in early phase clinical trials. The exact mechanism of action of this anticancer agent still needs to be clarified. We have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taraboletti, G, Poli, M, Dossi, R, Manenti, L, Borsotti, P, Faircloth, G T, Broggini, M, D'Incalci, M, Ribatti, D, Giavazzi, R
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2004
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409535/ https://www.ncbi.nlm.nih.gov/pubmed/15173857 http://dx.doi.org/10.1038/sj.bjc.6601864

Ejemplares similares

Effect of Aplidin in acute lymphoblastic leukaemia cells
por: Erba, E, et al.
Publicado: (2003)

Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine
por: Erba, E, et al.
Publicado: (2002)

Antitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myeloma
por: Caers, J, et al.
Publicado: (2008)

Establishment and characterisation of a human carcinoma cell line with acquired resistance to Aplidin™
por: Losada, A, et al.
Publicado: (2004)

Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel
por: Martinelli, M, et al.
Publicado: (2007)

In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells.
por: Depenbrock, H., et al.
Publicado: (1998)

Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents
por: Colella, G, et al.
Publicado: (1999)

Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts.
por: Giavazzi, R., et al.
Publicado: (1988)

IDN 5390: an oral taxane candidate for protracted treatment schedules
por: Pratesi, G, et al.
Publicado: (2003)

Cell cycle perturbations and apoptosis induced by isohomohalichondrin B (IHB), a natural marine compound
por: Bergamaschi, D, et al.
Publicado: (1999)

Mode of action of thiocoraline, a natural marine compound with anti-tumour activity
por: Erba, E, et al.
Publicado: (1999)

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
por: Bocci, G, et al.
Publicado: (2008)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

VEGF(165)b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy
por: Varey, A H R, et al.
Publicado: (2008)

The antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissues
por: Gaballah, K, et al.
Publicado: (2009)

Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers
por: Morbidelli, L, et al.
Publicado: (2003)

Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and endothelial cells in colorectal cancer
por: Ramcharan, K S, et al.
Publicado: (2014)

Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft
por: Petrangolini, G, et al.
Publicado: (2004)

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
por: Colmegna, B, et al.
Publicado: (2015)

Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach
por: Zeisberger, S M, et al.
Publicado: (2006)

Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224)
por: Doñate, F, et al.
Publicado: (2008)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

Editorial: Trabectedin, lurbinectedin, and other marine-derived anticancer alkaloids on solid cancer: Mechanisms of action, clinical impact, and future perspectives
por: Zambelli, Alberto, et al.
Publicado: (2023)

DNA damage and sequence specificity of DNA binding of the new anti-cancer agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate)
por: Broggini, M., et al.
Publicado: (1990)

Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action
por: Rusnati, Marco, et al.
Publicado: (2010)

L1210 cells selected for resistance to methoxymorpholinyl doxorubicin appear specifically resistant to this class of morpholinyl derivatives.
por: Geroni, C., et al.
Publicado: (1994)

The inefficacy of antiangiogenic therapies
por: Ribatti, Domenico
Publicado: (2010)

α-Bromoacryloyl derivative of distamycin A (PNU 151807): a new non-covalent minor groove DNA binder with antineoplastic activity
por: Marchini, S, et al.
Publicado: (1999)

The Aplidin analogs PM01215 and PM02781 inhibit angiogenesis in vitro and in vivo
por: Borjan, Bojana, et al.
Publicado: (2015)

Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts
por: Delgado-Calle, Jesus, et al.
Publicado: (2019)

Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743)
por: Erba, E, et al.
Publicado: (2000)

Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy
por: Awasthi, Niranjan, et al.
Publicado: (2022)

Determination of Paclitaxel Distribution in Solid Tumors by Nano-Particle Assisted Laser Desorption Ionization Mass Spectrometry Imaging
por: Morosi, Lavinia, et al.
Publicado: (2013)

Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors
por: Taraboletti, Giulia, et al.
Publicado: (2010)

Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A
por: Vacca, A, et al.
Publicado: (2002)

Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma
por: Ribatti, Domenico
Publicado: (2010)

3-methyladenine-DNA-glycosylase and O6-alkyl guanine-DNA-alkyltransferase activities and sensitivity to alkylating agents in human cancer cell lines.
por: Damia, G., et al.
Publicado: (1996)

A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate
por: Falasca, M, et al.
Publicado: (2010)

Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms
por: Romano, Michela, et al.
Publicado: (2017)

Response of chemically induced primary colon tumours of the mouse to flavone acetic acid (NSC 347 512).
por: Pratesi, G., et al.
Publicado: (1988)

Cannot write session to /tmp/vufind_sessions/sess_i6i0erimf0anj8mjvm0vc4ds0l